MiR-144 Suppresses Proliferation, Invasion, and Migration of Breast Cancer Cells Through Inhibiting CEP55

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2018 Mar 22

PMID 29561704

Citations 32

Authors

Yuanqin Yin

Jingjing Cai

Fandong Meng

Chengguang Sui

Youhong Jiang

Affiliations

Soon will be listed here.

Abstract

Objective: The study aimed to investigate the molecular mechanism of miR-144 and CEP55 as well as the influence of their interaction on the cell proliferation, migration, invasion, cell cycle and cell apoptosis in breast cancer.

Methods: In this study, The Cancer Genome Atlas (TCGA, https://tcga-data.nci.nih.gov/ ) database was used for microarray analysis. The expressions of miR-144 and CEP55 in 40 adjacent tissues and 36 tumor tissues were examined by western blot, qRT-PCR and immunohistochemistry. The target relationship between miR-144 and CEP55 was predicted and confirmed by TargetScan and luciferase reporter assay. The cell proliferation, cell cycle and cell apoptosis in different groups were detected by MTT and flow cytometry assays, while wound healing and transwell assays were used for the cell migration and invasion tests. The regulatory effects of miR-144 and CEP55 on breast tumor were verified through nude mouse model in vivo experiment.

Results: MiR-144 was down-regulated in breast cancerous tissues and cells, whereas CEP55 expression was up-regulated in breast cancerous tissues. Moreover, there existed a target relationship between miR-144 and CEP55 and negative correlation on their expressions. MiR-144 could down-regulate CEP55 expression, thereby inhibiting proliferation, invasion, migration, retarding cell cycle and accelerating cell apoptosis. MiR-144 could inhibit cell progression through down-regulating CEP55 in vivo.

Conclusion: MiR-144 suppressed cell proliferation, migration, invasion and induced cell cycle arrest and cell apoptosis by repressing CEP55. This might provide a promising therapy for clinical treatment.

Citing Articles

RNA binding protein ILF3 increases CEP55 mRNA stability to enhance malignant potential of breast cancer cells and suppress ferroptosis.

Chen S, Luo Y, Ruan S, Su G, Huang G Hereditas. 2025; 162(1):10.

PMID: 39871389 PMC: 11773698. DOI: 10.1186/s41065-025-00372-0.

Bioinformatic and experimental analyses of GATA3 and its regulatory miRNAs in breast Cancer.

Roohy F, Moghanibashi M, Tahmasebi S Discov Oncol. 2024; 15(1):588.

PMID: 39448444 PMC: 11502614. DOI: 10.1007/s12672-024-01479-y.

On discovery of novel hub genes for ER+ and TN breast cancer types through RNA seq data analyses and classification models.

Saddiqa A, Zakir M, Sheikh M, Muneer Z, Hassan A, Ali I Sci Rep. 2024; 14(1):20840.

PMID: 39242688 PMC: 11379961. DOI: 10.1038/s41598-024-69721-9.

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer.

Lambrechts Y, Garg A, Floris G, Punie K, Neven P, Nevelsteen I Genes Immun. 2023; 24(5):270-279.

PMID: 37759086 PMC: 10575765. DOI: 10.1038/s41435-023-00220-z.

MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes.

Ye Q, Raese R, Luo D, Cao S, Wan Y, Qian Y Cancers (Basel). 2023; 15(8).

PMID: 37190222 PMC: 10137184. DOI: 10.3390/cancers15082294.

References

Guo L, Yuan J, Xie N, Wu H, Chen W, Song S . miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer. Mol Med Rep. 2016; 14(4):2975-82. PMC: 5042781. DOI: 10.3892/mmr.2016.5645. View

Orso F, Quirico L, Virga F, Penna E, Dettori D, Cimino D . miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer. Cancer Res. 2016; 76(17):5151-62. DOI: 10.1158/0008-5472.CAN-15-1322. View

Sun J, Shi R, Zhao S, Li X, Lu S, Bu H . E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. J Exp Clin Cancer Res. 2017; 36(1):40. PMC: 5341194. DOI: 10.1186/s13046-017-0504-6. View

Chang Y, Wu C, Yen T, Ouyang P . Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1). J Biol Chem. 2011; 287(6):4376-85. PMC: 3281710. DOI: 10.1074/jbc.M111.289108. View

Wang Y, Jin T, Dai X, Xu J . Lentivirus-mediated knockdown of CEP55 suppresses cell proliferation of breast cancer cells. Biosci Trends. 2016; 10(1):67-73. DOI: 10.5582/bst.2016.01010. View

Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L . Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015; 21(10):1128-38. DOI: 10.1038/nm.3944. View

Kalniete D, Nakazawa-Miklasevica M, Strumfa I, Abolins A, Irmejs A, Gardovskis J . High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. Hered Cancer Clin Pract. 2015; 13(1):7. PMC: 4335782. DOI: 10.1186/s13053-015-0028-z. View

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Chen L, Li Y, Fu Y, Peng J, Mo M, Stamatakos M . Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One. 2013; 8(1):e54213. PMC: 3553092. DOI: 10.1371/journal.pone.0054213. View

10.

Pan H, Wen Z, Huang Y, Cheng X, Wang G, Zhou Y . Down-regulation of microRNA-144 in air pollution-related lung cancer. Sci Rep. 2015; 5:14331. PMC: 4585805. DOI: 10.1038/srep14331. View

11.

Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang Z . MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncol Rep. 2015; 34(4):1845-52. DOI: 10.3892/or.2015.4173. View

12.

Peng T, Zhou W, Guo F, Wu H, Wang C, Wang L . Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness. Sci Rep. 2017; 7(1):5925. PMC: 5517556. DOI: 10.1038/s41598-017-06132-z. View

13.

Chen C, Lu P, Chen Y, Fu S, Wu K, Tsou A . FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene. 2007; 26(29):4272-83. DOI: 10.1038/sj.onc.1210207. View

14.

Nygren M, Tekle C, Ingebrigtsen V, Makela R, Krohn M, Aure M . Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer. 2014; 110(8):2072-80. PMC: 3992492. DOI: 10.1038/bjc.2014.113. View

15.

Jiang W, Wang Z, Chen G, Jia Y . Prognostic significance of centrosomal protein 55 in stage I pulmonary adenocarcinoma after radical resection. Thorac Cancer. 2016; 7(3):316-22. PMC: 4846620. DOI: 10.1111/1759-7714.12330. View

16.

Keller A, Leidinger P, Vogel B, Backes C, ElSharawy A, Galata V . miRNAs can be generally associated with human pathologies as exemplified for miR-144. BMC Med. 2014; 12:224. PMC: 4268797. DOI: 10.1186/s12916-014-0224-0. View

17.

Fabbro M, Zhou B, Takahashi M, Sarcevic B, Lal P, Graham M . Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev Cell. 2005; 9(4):477-88. DOI: 10.1016/j.devcel.2005.09.003. View

18.

Hu H, Gatti R . MicroRNAs: new players in the DNA damage response. J Mol Cell Biol. 2010; 3(3):151-8. PMC: 3104011. DOI: 10.1093/jmcb/mjq042. View

19.

Chen S, Li P, Li J, Wang Y, Du Y, Chen X . MiR-144 inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR. Cell Physiol Biochem. 2015; 35(3):997-1007. DOI: 10.1159/000369755. View

20.

Jiang W, Wang Z, Jia Y . CEP55 overexpression predicts poor prognosis in patients with locally advanced esophageal squamous cell carcinoma. Oncol Lett. 2017; 13(1):236-242. PMC: 5244839. DOI: 10.3892/ol.2016.5414. View